Endocrinologists’ Perceived Benefits and Risks of Digital Transformation for Growth Disorders Care in Taiwan: An Expert Panel Discussion

Abstract

Digital health technologies have gained acceptance in paediatric growth hormone (GH) therapy, supporting patients and caregivers in their treatment journey with healthcare professionals (HCPs) playing a pivotal role. Understanding HCPs’ perspectives regarding the adoption and recommendation of digital health devices with a connected ecosystem for remote monitoring of real-time adherence is essential for aiding clinical decisions and timely interventions. The results from a participatory workshop in Taiwan involving nine paediatric endocrinologists, exploring the risks and benefits of integrating digital health solutions such as Aluetta® with Smartdot™ and Growzen™ ecosystem (Merck Healthcare KGaA, Darmstadt, Germany) for GH therapy are presented. These findings emphasise the importance of novelty in digitalisation and evidence-based treatment strategies to motivate patients achieve growth improvement.